This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

PROMUS™ Element™ Everolimus-Eluting Coronary Stent System European Post-Approval Surveillance Study (PE-Prove)

This study has been completed.
Sponsor:
Collaborators:
Pharmaceutical Research Associates
Medidata Solutions
Information provided by (Responsible Party):
Boston Scientific Corporation
ClinicalTrials.gov Identifier:
NCT01148329
First received: June 21, 2010
Last updated: February 1, 2017
Last verified: February 2017
June 21, 2010
February 1, 2017
June 2010
June 2012   (Final data collection date for primary outcome measure)
Target Vessel Failure (TVF) [ Time Frame: One year ]
Overall and PROMUS™ Element™ stent related TVF rate (cardiac death, myocardial infarction (MI) related to target vessel and target vessel re-intervention (TVR)) at 12 months post stent implantation.
Target Vessel Failure [ Time Frame: One year ]
Overall and PROMUS™ Element™ stent related TVF rate (cardiac death, myocardial infarction (MI) related to target vessel and target vessel re-intervention (TVR)) at 12 months post stent implantation.
Complete list of historical versions of study NCT01148329 on ClinicalTrials.gov Archive Site
  • Major Adverse Cardiac Events (MACE) rates (cardiac death, MI, TVR) [ Time Frame: 30 days, 6 months, 12 months and then annually through 5 years ]
    Overall and PROMUS™ Element™ stent-related MACE rates (cardiac death, MI, TVR).
  • Death or MI rates [ Time Frame: 30 days, 6 months, 12 months and then annually through 5 years ]
    Overall and PROMUS™ Element™ stent-related cardiac death or MI rates
  • TVR rates [ Time Frame: 30 days, 6 months, 12 months and then annually through 5 years ]
    Overall and PROMUS™ Element™ stent-related TVR rates.
  • Cardiac death rates [ Time Frame: 30 days, 6 months, 12 months and then annually through 5 years ]
    Overall and PROMUS™ Element™ stent-related cardiac death rates.
  • MI Rates [ Time Frame: 30 days, 6 months, 12 months and then annually through 5 years ]
    Overall and PROMUS™ Element™ stent-related MI rates.
  • All death rates [ Time Frame: 30 days, 6 months, 12 months and then annually through 5 years ]
    All death rates
  • Non-cardiac death rates [ Time Frame: 30 days, 6 months, 12 months and then annually through 5 years ]
    Non-cardiac death rates
  • All death or MI rates [ Time Frame: 30 days, 6 months, 12 months and then annually through 5 years ]
    All death and MI rates
  • MACE rates (cardiac death, MI, TVR) [ Time Frame: 30 days, 6 months, 12 months and then annually through 5 years ]
    Overall and PROMUS™ Element™ stent-related MACE rates (cardiac death, MI, TVR).
  • Death or MI rates [ Time Frame: 30 days, 6 months, 12 months and then annually through 5 years ]
    Overall and PROMUS™ Element™ stent-related cardiac death or MI rates
  • TVR rates [ Time Frame: 30 days, 6 months, 12 months and then annually through 5 years ]
    Overall and PROMUS™ Element™ stent-related TVR rates.
  • Cardiac death rates [ Time Frame: 30 days, 6 months, 12 months and then annually through 5 years ]
    Overall and PROMUS™ Element™ stent-related cardiac death rates.
  • MI Rates [ Time Frame: 30 days, 6 months, 12 months and then annually through 5 years ]
    Overall and PROMUS™ Element™ stent-related MI rates.
  • All death rates [ Time Frame: 30 days, 6 months, 12 months and then annually through 5 years ]
    All death rates
  • Non-cardiac death rates [ Time Frame: 30 days, 6 months, 12 months and then annually through 5 years ]
    Non-cardiac death rates
  • All death or MI rates [ Time Frame: 30 days, 6 months, 12 months and then annually through 5 years ]
    All death and MI rates
Not Provided
Not Provided
 
PROMUS™ Element™ Everolimus-Eluting Coronary Stent System European Post-Approval Surveillance Study
PROMUS™ Element™ Everolimus-Eluting Coronary Stent System European Post- Approval Surveillance Study To Evaluate Real World Clinical Outcomes Data for the PROMUS™ Element™ Coronary Stent System in Unselected Patients in Routine Clinical Practice
The goal of the PROMUS™ Element™ Everolimus-Eluting Coronary Stent System European Post- Approval Surveillance Study is to evaluate real world clinical outcomes data for the PROMUS™ Element™ Coronary Stent System in unselected patients in routine clinical practice.
Not Provided
Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample
All patients who are candidates for Coronary artery stenting, signed the Informed Consent Form and are eligible to receive a PROMUS™ Element™ stent will be evaluated for enrollment in this study.
Coronary Heart Disease
Device: Coronary stenting
The PROMUS™ Element™ Everolimus Eluting Coronary Stent System is indicated for improving coronary luminal diameter in patients with symptomatic ischemic heart disease due to discrete de novo native coronary artery lesions. The treated lesion length should be less than the nominal stent length (8 mm, 12 mm, 16 mm, 20 mm, 24 mm, 28 mm, 32 mm, 38mm) with a reference vessel diameter of 2.25 mm - 4.0 mm.
Single arm observational study
To evaluate real world clinical outcomes data for the PROMUS™ Element™ Coronary Stent System in unselected patients in routine clinical practice
Intervention: Device: Coronary stenting
Thomas MR, Birkemeyer R, Schwimmbeck P, Legrand V, Moreno R, Briguori C, Werner N, Bramucci E, Ungi I, Richardt G, Underwood PL, Dawkins KD. One-year outcomes in 1,010 unselected patients treated with the PROMUS Element everolimus-eluting stent: the multicentre PROMUS Element European Post-Approval Surveillance Study. EuroIntervention. 2015 Mar;10(11):1267-71. doi: 10.4244/EIJY15M01_07.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
1010
December 2016
June 2012   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • According to Instructions For Use

Exclusion Criteria:

  • Contraindications according to Instructions for Use
Sexes Eligible for Study: All
Child, Adult, Senior
No
Contact information is only displayed when the study is recruiting subjects
Austria,   Belgium,   Denmark,   France,   Germany,   Hungary,   Ireland,   Italy,   Netherlands,   Spain,   United Kingdom
Sweden
 
NCT01148329
S2057
No
Not Provided
Plan to Share IPD: No
Plan Description: Data are presented at the 2013 EuroPCR congress.
Boston Scientific Corporation
Boston Scientific Corporation
  • Pharmaceutical Research Associates
  • Medidata Solutions
Principal Investigator: Raul Moreno, MD PhD Hospital La Paz, Spain
Study Director: Peter Maurer, PhD Boston Scientific Corporation
Boston Scientific Corporation
February 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP